Suppr超能文献

从混合人免疫球蛋白中依次纯化的病原体反应性抗体的治疗潜力

Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin.

作者信息

Reglinski Mark, Sriskandan Shiranee

机构信息

Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK.

出版信息

BMC Res Notes. 2019 Apr 15;12(1):228. doi: 10.1186/s13104-019-4262-8.

Abstract

OBJECTIVE

Intravenous immune globulin (IVIG), pooled from human blood, is a polyspecific antibody preparation that inhibits the super-antigenic proteins associated with streptococcal and staphylococcal toxic shock, and the Shiga toxin. In addition to this toxin-neutralising activity, IVIG contains other pathogen-reactive antibodies that may confer additional therapeutic benefits. We sought to determine if pathogen-reactive antibodies that promote opsonophagocytosis of different organisms can be sequentially affinity-purified from one IVIG preparation.

RESULTS

Antibodies that recognise cell wall antigens of Streptococcus pyogenes, Staphylococcus aureus, and vancomycin-resistant enterococcus (VRE) were sequentially affinity-purified from a single preparation of commercial IVIG and opsonophagocytic activity was assessed using a flow cytometry assay of neutrophil uptake. Non-specific IgG-binding proteins were removed from the S. aureus preparations using an immobilised Fc fragment column, produced using IVIG cleaved with the Immunoglobulin G-degrading enzyme of S. pyogenes (IdeS). Affinity-purified anti-S. aureus and anti-VRE immunoglobulin promoted significantly higher levels of opsonophagocytic uptake by human neutrophils than IVIG when identical total antibody concentrations were compared, confirming activity previously shown for affinity-purified anti-S. pyogenes immunoglobulin. The opsonophagocytic activities of anti-S. pyogenes, anti-S. aureus, and anti-VRE antibodies that were sequentially purified from a single IVIG preparation were undiminished compared to antibodies purified from previously unused IVIG.

摘要

目的

静脉注射免疫球蛋白(IVIG)是一种从人血液中提取的多特异性抗体制剂,可抑制与链球菌和葡萄球菌中毒性休克相关的超抗原蛋白以及志贺毒素。除了这种毒素中和活性外,IVIG还含有其他病原体反应性抗体,可能带来额外的治疗益处。我们试图确定能否从一种IVIG制剂中依次亲和纯化出促进不同生物体调理吞噬作用的病原体反应性抗体。

结果

从单一商业IVIG制剂中依次亲和纯化出识别化脓性链球菌、金黄色葡萄球菌和耐万古霉素肠球菌(VRE)细胞壁抗原的抗体,并使用中性粒细胞摄取的流式细胞术测定法评估调理吞噬活性。使用固定化Fc片段柱从金黄色葡萄球菌制剂中去除非特异性IgG结合蛋白,该柱由用化脓性链球菌免疫球蛋白G降解酶(IdeS)裂解的IVIG制备而成。当比较相同总抗体浓度时,亲和纯化的抗金黄色葡萄球菌和抗VRE免疫球蛋白促进人中性粒细胞的调理吞噬摄取水平明显高于IVIG,证实了先前针对亲和纯化的抗化脓性链球菌免疫球蛋白所显示的活性。与从先前未使用的IVIG中纯化的抗体相比,从单一IVIG制剂中依次纯化的抗化脓性链球菌、抗金黄色葡萄球菌和抗VRE抗体的调理吞噬活性并未降低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验